An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

NCT01990248 · clinicaltrials.gov ↗
COMPLETED
Status
339
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Hoffmann-La Roche